CAMBRIDGE, UK – 6 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce that its Chief Medical Officer, Dr Michael Koslowski has been listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology. Based on the number of patents granted, the annual ranking of faculty is published in the bioentrepreneur section of the publication.
Michael Koslowski was granted 10 patents in 2015. His most cited patents titles include monoclonal antibodies for the treatment of cancer and the identification of tumour-associated antigens for diagnosis and therapy.
Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We are very pleased that Michael has been recognised for his stellar work to date, and are delighted that he is part of our team to support our growth strategy as we continue to transition our business into a clinical stage organisation. Michael’s experience and in-depth knowledge of clinical development enables us to further advance our DUB platform. With a wealth of international, commercial and scientific experience, our team continues to create and deliver value from the diverse therapeutic opportunities generated by our discovery platform.”
The full ranking can be found here:
For more information:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 20 7862 6390
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.
Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.